Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - ALLOS THERAPEUTICS INC | d338145dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 20, 2012 (April 20, 2012)
ALLOS THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 000-29815 | 54-1655029 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
11080 CirclePoint Road, Suite 200
Westminster, Colorado 80020
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (303) 426-6262
N/A
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events |
On April 20, 2012, Allos Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing that the European Medicines Agency’s Committee For Medicinal Products for Human Use confirmed its previous negative opinion issued in January 2012 on the Company’s marketing authorisation application for FOLOTYN® (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma whose disease has progressed after at least one prior systemic therapy. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
| 99.1 | Press Release, dated April 20, 2012, entitled “Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated as of April 20, 2012
| ALLOS THERAPEUTICS, INC. | ||
| By: | /s/ Marc H. Graboyes | |
| Name: | Marc H. Graboyes | |
| Title: | Senior Vice President, General Counsel | |
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated April 20, 2012, entitled “Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe.” | |